Technical advance

Quantitation of DNA methylation by melt curve analysis

Eric Smith¹, Michael E Jones² and Paul A Drew*³

Address: ¹Discipline of Surgery, School of Medicine, The University of Adelaide, Royal Adelaide Hospital, South Australia 5005, Australia, ²School of Medicine, Flinders University, Bedford Park, South Australia 5042, Australia and ³School of Nursing and Midwifery, Flinders University, Bedford Park, South Australia 5042, Australia

Email: Eric Smith - eric.smith@adelaide.edu.au; Michael E Jones - michael.e.jones@flinders.edu.au; Paul A Drew* - paul.drew@flinders.edu.au

* Corresponding author

Abstract

Background: Methylation of DNA is a common mechanism for silencing genes, and aberrant methylation is increasingly being implicated in many diseases such as cancer. There is a need for robust, inexpensive methods to quantitate methylation across a region containing a number of CpGs. We describe and validate a rapid, in-tube method to quantitate DNA methylation using the melt data obtained following amplification of bisulfite modified DNA in a real-time thermocycler.

Methods: We first describe a mathematical method to normalise the raw fluorescence data generated by heating the amplified bisulfite modified DNA. From this normalised data the temperatures at which melting begins and finishes can be calculated, which reflect the less and more methylated template molecules present respectively. Also the T50, the temperature at which half the amplicons are melted, which represents the summative methylation of all the CpGs in the template mixture, can be calculated. These parameters describe the methylation characteristics of the region amplified in the original sample.

Results: For validation we used synthesized oligonucleotides and DNA from fresh cells and formalin fixed paraffin embedded tissue, each with known methylation. Using our quantitation we could distinguish between unmethylated, partially methylated and fully methylated oligonucleotides mixed in varying ratios. There was a linear relationship between T50 and the dilution of methylated into unmethylated DNA. We could quantitate the change in methylation over time in cell lines treated with the demethylating drug 5-aza-2'-deoxycytidine, and the differences in methylation associated with complete, clonal or no loss of MGMT expression in formalin fixed paraffin embedded tissues.

Conclusion: We have validated a rapid, simple in-tube method to quantify methylation which is robust and reproducible, utilizes easily designed primers and does not need proprietary algorithms or software. The technique does not depend on any operator manipulation or interpretation of the melt curves, and is suitable for use in any laboratory with a real-time thermocycler. The parameters derived provide an objective description and quantitation of the methylation in a specimen, and can be used to for statistical comparisons of methylation between specimens.
Background

Methylation of DNA is a common epigenetic change which is important for the normal functioning of the cell. Methylation occurs almost exclusively on cytosines in the setting of a CpG dinucleotide. Most CpGs are methylated in the genome, except for those in the majority of CpG dense regions (CpG islands) found at the 5' end of around 50% of mammalian genes. Abnormal methylation is implicated in a number of disease processes. This applies particularly in cancer where there is genome wide hypomethylation together with hypermethylation of many CpG islands, which can silence tumor suppressor genes. There is great interest in assessing methylation because it may have diagnostic or prognostic value, or be a predictive marker for therapy. It is therefore important to have simple, accurate and inexpensive techniques for measuring methylation, which are suitable for use in a range of laboratories.

There are a number of qualitative and quantitative methods for the analysis of methylation, each with its own advantages and disadvantages [1,2]. Many of these methods rely on treating the DNA with sodium bisulfite. This deaminates unmethylated cytosines to uracils while methylated cytosines remain unchanged, resulting in templates that differ in sequence between the unmethylated and methylated forms. Regions can be amplified by PCR using primers specific for bisulfite modified DNA and, depending on the design of the assay, the methylation status of individual CpGs, or of a region containing a number of CpGs, can then be obtained. Techniques which measure the methylation at each CpG within a target region include bisulfite sequencing [3], pyrosequencing [4], and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) [5]. These techniques are relatively expensive to perform, require multiple steps, are time consuming, or require expensive hardware that is not readily available in many laboratories. The commonly used methylation-specific PCR (MSP) [6] does not suffer from these disadvantages, but the primers are more demanding to design, and the assay only measures methylation of CpGs located near the 3' end of the primers.

For many purposes an estimate of the overall methylation of all CpGs within a region is as useful as knowing the methylation at specific CpGs. We describe an objective assessment of overall methylation using melt curve analysis, a technique first described by Ririe to differentiate between desired and undesired products of a PCR [7]. In melt curve analysis PCR products are slowly heated in the presence of double-stand DNA (dsDNA) specific fluorescent dyes such as SYBR Green I, LCGreen, SYTO9 or EvaGreen. With increasing temperature the dsDNA denatures (melts), releasing the fluorescent dye with a resultant decrease in the fluorescent signal. The temperature at which dsDNA melts is determined by factors such as nucleotide sequence, length and GC/AT ratio. A methylated sequence of DNA, following bisulfite modification, will maintain a higher GC/AT ratio and so melt at a higher temperature than its unmethylated equivalent. Melt curve analysis can detect a single base difference [8]. Worm applied this principle to DNA methylation analysis [9], and a number of variations have since been described, such as methylation-sensitive high resolution melting [10] and dissociation analysis [11]. In each of these methods methylation is assessed visually. In melting curve analysis-methylation (MCA-Meth) the ratio of methylated to unmethylated amplicons was calculated from the respective heights of the derivative peaks (-dF/dT), but this method of quantitation cannot be applied to samples containing partially methylated molecules [12].

We describe a simple mathematical approach to generate normalised melt curves from the raw fluorescence melt data obtained following PCR. We can then calculate from the normalised melt curve the melt temperature (T50), the temperature at which 50% of the molecules in the PCR product are melted, which reflects the average methylation of all the CpGs in the region amplified, and the temperatures at which melting begins and is complete, which reflect the heterogeneity of methylation of the alleles within the amplified region. These parameters provide an objective description and quantitation of the homogeneous and heterogeneous methylation in a specimen, and can be used to compare methylation between specimens.

Methods

Primers and oligonucleotides

Primers (Table 1), and oligonucleotide sequences representing the bisulfite modified fragments of the CDKN2A promoter (Table 2), were synthesized by GeneWorks (Thebarton, SA, Australia). Primers for melt curve analysis were designed to amplify both methylated and unmethylated bisulfite modified DNA, but not unmodified DNA. Our primer design guidelines were as follows.

1. They should contain at least one T corresponding to a non-CpG C within the last three nucleotides at the 3'-end of the primer, to increase the likelihood of amplification of only bisulfite modified template.

2. They should not contain CpGs, but when this is unavoidable the number of CpGs are minimised and placed as far as possible toward the 5'-end of the primer. In these cases primers are designed with either an inosine or a degenerate base (C/T in the forward primer, or G/A in the reverse primer) so that templates with both methylated and unmethylated CpGs would be amplified.

For many purposes an estimate of the overall methylation of all CpGs within a region is as useful as knowing the methylation at specific CpGs. We describe an objective assessment of overall methylation using melt curve analysis, a technique first described by Ririe to differentiate between desired and undesired products of a PCR [7]. In melt curve analysis PCR products are slowly heated in the presence of double-stand DNA (dsDNA) specific fluorescent dyes such as SYBR Green I, LCGreen, SYTO9 or EvaGreen. With increasing temperature the dsDNA denatures (melts), releasing the fluorescent dye with a resultant decrease in the fluorescent signal. The temperature at which dsDNA melts is determined by factors such as nucleotide sequence, length and GC/AT ratio. A methylated sequence of DNA, following bisulfite modification, will maintain a higher GC/AT ratio and so melt at a higher temperature than its unmethylated equivalent. Melt curve analysis can detect a single base difference [8]. Worm applied this principle to DNA methylation analysis [9], and a number of variations have since been described, such as methylation-sensitive high resolution melting [10] and dissociation analysis [11]. In each of these methods methylation is assessed visually. In melting curve analysis-methylation (MCA-Meth) the ratio of methylated to unmethylated amplicons was calculated from the respective heights of the derivative peaks (-dF/dT), but this method of quantitation cannot be applied to samples containing partially methylated molecules [12].

We describe a simple mathematical approach to generate normalised melt curves from the raw fluorescence melt data obtained following PCR. We can then calculate from the normalised melt curve the melt temperature (T50), the temperature at which 50% of the molecules in the PCR product are melted, which reflects the average methylation of all the CpGs in the region amplified, and the temperatures at which melting begins and is complete, which reflect the heterogeneity of methylation of the alleles within the amplified region. These parameters provide an objective description and quantitation of the homogeneous and heterogeneous methylation in a specimen, and can be used to compare methylation between specimens.
Table 1: Primers used in this study

| Gene | Primer sequences 5'-3' | Locationa | Sizeb | CpGs c |
|------|-----------------------|------------|-------|--------|
| CDKN2A | Forward-GAAGAAAGAGGGTTGTTGTTATT  Reverse-ACCTACTCTCCCCCTTCGCAA | chr:9:21964847 – 21964930 | 84 | 6 |
| TIMP3 | Forward-GGGGGTTATTTTTTTATAGATTG  Reverse-AAACCCCRCTCAGCTTTAAAA | chr:22:31527488 – 31527645 | 158 | 10 |
| MGMT | Forward-IGGTGGATGATGTTGGGATTAGT  Reverse-ACTAAACCAACACTCACCACA | chr:10:131155461 – 131155570 | 110 | 12 |

Y – C/T  
R – A/G  
I – inosine  

aGenome location, as determined by UCSC Genome Browser Database (GBD, http://genome.ucsc.edu) Human March 2006 (hg18) assembly.  
bSize of the PCR product.  
cNumber of CpGs in the PCR product between the primer binding sites.

3. There should be limited self-complementarity and limited complementary sequences between primer pairs. These parameters can be assessed using freely available software tools including Oligo Calc: Oligonucleotide Properties Calculator to test for self-complementarity (http://www.basic.northwestern.edu/biotools/oligo calc.html) and Amplify (version 3.1.4, http:// engels.genetics.wisc.edu) to test for potential primer-dimers.

4. They should amplify a product which is approximately 80 – 160 bp in length.

5. The primers should be approximately 20 – 30 bp in length.

6. The primer pairs should have melting temperatures as similar as possible, but differ by no more than 2°C.

Reference DNA

Bisulfite modified genomic DNA prepared from the lymphocytes of healthy donors was used as unmethylated reference [13]. For the methylated reference, 2 μg of lymphocyte genomic DNA was treated with 10 U of M.SssI CpG Methylase (New England BioLabs Inc., Beverly, MA, USA) for 16 h at 37°C in a 50 μL reaction volume containing 160 μM S-adenosylmethionine and NEBuffer 2 (50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2, 1 mM dithiothreitol, pH 7.9). Methylase treated DNA was precipitated with 150 μL of 100% ethanol and centrifuged for 15 min at 4°C. The ethanol was removed and the DNA pellet was air-dried under vacuum. The DNA was resuspended in 18 μL of ultra-pure water (UPW, Fisher Biotec Australia, West Perth, WA, Australia), and bisulfite modified.

Cell culture

The esophageal adenocarcinoma cell line OE33 was cultured in RPMI 1640 supplemented with 10% foetal bovine serum, at 37°C, in air enriched with 5% CO2. Triplicate cultures of OE33 were grown for 24 h, then treated with either 1 μM 5-aza-2’-deoxycytidine (aza) (Sigma-Aldrich, Saint Louis, MO, USA) or vehicle (0.0027% v/v final concentration acetic acid) for 48, 72 or 120 h. The cells were incubated for a further 24 h in fresh medium not containing aza or vehicle and harvested. The DNA was isolated using TRIzol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions.

Table 2: Oligonucleotide sequences representing a fragment of the CDKN2A promoter

| Oligonucleotide | Sequence |
|----------------|----------|
| Unmethylated | gaagaaagggggttggtttgg | TGatTTGTGctTGtTGtTGtCGetGgagagagagagagatT |
| Partially methylated | gaagaaagggggttggtttgg | TGatTTGTGctTGtTGtTGtCGetGgagagagagagagatT |
| Fully methylated | gaagaaagggggttggtttgg | TGgtTTGTGctTGtTGtTGtCGetGgagagagagagagatT |

The oligonucleotide sequences representing a bisulfite modified fragment of the CDKN2A promoter that were either unmethylated, partially methylated, or fully methylated. The sequence to which the primers bind is underlined. The location of the six CpGs between the primer binding sites are in bold. Thymines which are generated following bisulfite modification and amplification are capitalised.
Bisulfite modification
Genomic DNA (2 μg) was bisulfite modified as previously described [14,15]. Bisulfite modified DNA from lymphocytes and cell lines were resuspended in UPW at a volume of 100 μL, and from FFPE tissue in a volume of 20 μL.

PCR and melt analysis
Bisulfite modified DNA (1 μL) was amplified using QuantiTect SYBR Green PCR Kit (Qiagen, Hilden, Germany) containing a final concentration of 0.5 μM of each primer (Table 1) in a final reaction volume of 15 μL. The primers and PCR conditions were specific for bisulfite modified DNA, and did not amplify unmodified DNA. The PCR was performed using a Rotor-Gene 3000 (RG3000, Corbett Life Science, Sydney, NSW, Australia) with a 95°C activation step for 15 min; 95°C for 30 s, 55°C for 60 s for 45 cycles; and a final extension step of 72°C for 4 min. The melt of the PCR product was performed from 60 to 90°C, rising in 0.5°C increments, 55°C for 60 s for 45 cycles; and a final extension step of 72°C for 4 min. The melt of the PCR product was performed from 60 to 90°C, rising in 0.5°C increments, waiting for 30 s at the first step and for 5 s at each step thereafter, and acquiring fluorescence at each temperature increment.

Statistics
Two groups were compared using the Wilcoxon-Mann-Whitney test, and three groups were compared using the Kruskal-Wallis one-way analysis of variance by ranks [16]. More than three groups were compared with one-way analysis of variance with Tukey multiple comparison post-test. All statistics were considered significant when the two tailed P = 0.05.

Results
Algorithm: analysis of melt curves from raw melt data
A graph of the raw fluorescence plotted against temperature for a typical melt of dsDNA PCR products using the RG3000 is shown in Figure 1A. The magnitude of the starting fluorescence often varies significantly between samples, making direct comparisons difficult. To facilitate comparisons, the raw fluorescence data can be normalised, as described below. Figure 1B shows that the graph of raw melt data for a sample has three distinguishable phases. In Phase 1 there is a linear decrease in fluorescence with increasing temperature. This decrease can be represented mathematically. There is a constant background amount of fluorescence, and added to this is a linearly decreasing amount which can be calculated from the regression line which best fits the fluorescent data over the linear reduction phase (represented as a solid blue line in Figure 1B). In Phase 2, the rapid reduction in fluorescence is a combination of the linear decrease and the melting of dsDNA. During this phase the observed fluorescence \( F(T)_{obs} \) is less than the fluorescence expected from the Phase 1 alone \( F(T)_{max} \). In Phase 3, the final plateau phase, the dsDNA is fully melted and there is no further decline in fluorescence.

At each temperature point it is possible to calculate how much fluorescence is lost as a result of melting of the dsDNA. The amount of fluorescence in the sample at any given temperature, if the dsDNA does not melt and assuming that the reduction in fluorescence is linear with increasing temperature, can be calculated from the extrapolation of the regression line of the Phase 1 decline. The reduction in fluorescence \( F(T)melt \) due to the melting of the dsDNA at any given temperature, is the difference between the fluorescence predicted at that temperature from the regression line \( F(T)_{max} \) and the observed value \( F(T)_{obs} \), or \( F(T)melt = F(T)_{max} - F(T)_{obs} \).

The normalised fluorescence at any given temperature is the ratio of the amount of fluorescence observed to the amount of fluorescence predicted if no melting of the dsDNA had occurred \( F(T)_{obs}/F(T)_{max} \), expressed as a percentage. Normalised fluorescence values can then plotted against temperature as normalised melt curves (Figure 1C). The initial phase is a flat line, as there is no reduction in fluorescence due to specific dsDNA melting. Reduction in fluorescence due to specific melting of the dsDNA begins at the take-off temperature \( Tto \) and finishes at the touch down temperature \( Ttd \), where the fluorescence reaches background. We calculated these as the 95% and 5% percentile fluorescence respectively, but other values could be easily used.

Normalising the raw melt data facilitates comparisons between melt curves of different samples, and to unmethylated and fully methylated DNA references. Two parameters which describe the methylation of the population of DNA templates for the region amplified can be determined from the normalised curve. The temperature range over which melting occurs, the difference between take-off and touchdown temperatures \( Ttd - Tto \), will be greater if there is a mixture of methylated and unmethylated molecules than if there is a homogeneous population, making this a measure of methylation heterogeneity. The extent of methylation of the population can be described by the temperature at which half the dsDNA molecules are melted and half are intact \( T50 \). The higher the \( T50 \), the more the methylation in the DNA population. The normalised melt curve and the individual
Figure 1

**Raw and normalised melt curves.** A) Typical examples of raw fluorescence melt curves. Six replicates of an oligonucleotide representing a fragment of the unmethylated CDKN2A promoter were amplified using the CDKN2A primers and QuantiTect SYBR Green PCR Kit, then melted by increasing the temperature from 60 to 90°C, rising in 0.5°C increments, waiting for 30 s at the first step and for 5 s at each step thereafter, acquiring fluorescence at each increment. Raw fluorescence was plotted against temperature. The plots show that the magnitude of the starting fluorescence may vary significantly even between replicates. B) Graph of raw fluorescence plotted against temperature from one sample from Figure 1A shows that there are three distinguishable phases. In Phase 1 there is a linear decrease in fluorescence with increasing temperature (represented as a solid blue line). In Phase 2 there is a rapid reduction in fluorescence which is a combination of the linear decrease and the melting of dsDNA. During Phase 2 the observed fluorescence ($F(T)_{obs}$) is less than the fluorescence expected from the Phase 1 alone ($F(T)_{max}$). The reduction in fluorescence due to the melting of the dsDNA alone at any given temperature (vertical dotted red line) is the difference between $F(T)_{max}$ and $F(T)_{obs}$, $F(T)_{melt}$ (solid red line with arrow heads). In Phase 3 the dsDNA is fully melted and there is no further decline in fluorescence. C) Normalised melt curves for the six replicates in Figure 1A. The normalised fluorescence was calculated by the formula $F(T)_{obs}/F(T)_{max}$ at every given temperature increment. Normalised fluorescence expressed as a percentage was then plotted against temperature.
parameters derived from it can be simply computed using the raw fluorescence data exported from the real-time thermocycler or other microvolume fluorometer integrated with a rapid temperature cycler.

**Melt curve analysis of synthesised oligonucleotides**

We tested the application of this analysis using synthesized oligonucleotides of known methylation. Three different oligonucleotides were synthesised, each representing a bisulfite modified DNA fragment of the same region of the CDKN2A promoter but differing in the extent of methylation, the number of methylated CpGs in the sequence. These CDKN2A oligonucleotide sequences are shown in Table 2. The region was 84 nucleotides long, and contained seven CpGs in total, six CpGs between the primer binding sites. In the oligonucleotide representing unmethylated bisulfite modified CDKN2A, the cytosines of the six CpGs were substituted with thymines. For the methylated oligonucleotide these cytosines remained as cytosines. For the partially methylated oligonucleotide three of the cytosines were substituted with thymines, the other three remained as cytosines.

Figure 2A shows the derivative peaks (-dF/dT), and Figure 2B the normalised melt curves, calculated as described, for the PCR products amplified from each of the three oligonucleotides. The general shapes of the -dF/dT plots and the normalised curves are similar, but they are hotter in proportion to the extent of methylation. The melt curve for the partially methylated oligonucleotide (three cytosines and three thymines) is between that of the unmethylated and methylated oligonucleotides. The T50, Tto and Tdo significantly increased with the extent of methylation (Table 3; P < 0.005 for all comparisons), demonstrating that differences could be measured between oligonucleotides which differed by as few as three methylated CpGs per molecule. The normalised melt curves did not differ whether the PCR products were melted immediately at the end of the PCR, or on a subsequent day, or had been melted a number of times before, even though the magnitude of the fluorescence intensity may have decreased over the time (data not shown).

Next, we investigated the ability of the method to analyse a mixture of two different oligonucleotides. Unmethylated oligonucleotide was spiked with either partially or fully methylated oligonucleotide, amplified and then melted. Spiking the unmethylated oligonucleotide with either partially methylated (U/P) or fully methylated (U/M) oligonucleotide significantly altered the shape of the -dF/dT (Figure 2C) and the normalised (Figure 2D) melt curves. The spiking did not significantly alter Tto, but did significantly increase T50 and Ttd in proportion to the extent of methylation of the spiked mixture (Table 3; P < 0.005 for all comparisons).

**Melt curve analysis of mixtures of methylated and unmethylated cell DNA**

To determine the relationship between T50 and the ratio of methylated to unmethylated molecules, we made dilutions of methylated reference DNA into unmethylated reference DNA. The dilutions were amplified using TIMP3 primers, the products melted, and the melt data normalised (Figure 3A). A visible shift to the right of the unmethylated reference was observed when 5% of the template molecules were methylated. There was a linear correlation between the percentage of methylated molecules in the mixture and the T50 (Figure 3B). Similar results were observed for regions of the CDKN2A and MGMT genes, except that shifts in the melt curves could be detected when 1% of the template molecules were methylated (data not shown).

**Melt curve analysis of cell line DNA**

To validate melt curve analysis in cell line DNA we looked for a correlation between the melt curve parameters and the reduction in methylation in a cell line cultured with the demethylating agent 5-aza-2’-deoxycytidine (aza). We have previously shown that TIMP3 is methylated in the OE33 cell line, and that with aza treatment TIMP3 methylation is reduced and expression increased [14,15]. The results in Figure 4 show the normalised melt curves for DNA isolated from cells treated with vehicle or aza for 48, 72 or 120 h. Compared to unmethylated and methylated reference, all normalised melt curves for vehicle treated

---

**Table 3: T50, Tto, Ttd and Ttd – Tto values for known oligonucleotides**

| Oligonucleotide | T50     | Tto     | Ttd     | Ttd – Tto |
|-----------------|---------|---------|---------|-----------|
| Unmethylated    | 79.07 ± 0.06 | 78.48 ± 0.05 | 80.60 ± 0.06 | 2.12 ± 0.07 |
| Partially methylated | 80.00 ± 0.26 | 78.85 ± 0.53 | 82.39 ± 0.17 | 3.54 ± 0.47 |
| Fully methylated | 82.10 ± 0.00 | 81.13 ± 0.05 | 84.29 ± 0.03 | 3.16 ± 0.15 |
| U/P             | 79.27 ± 0.21 | 81.30 ± 0.05 | 81.47 ± 0.18 | 3.17 ± 0.15 |
| U/M             | 80.17 ± 0.15 | 78.45 ± 0.11 | 83.36 ± 0.19 | 4.90 ± 0.21 |

U/P – unmethylated oligonucleotide spiked with partially methylated oligonucleotide.

U/M – unmethylated oligonucleotide spiked with fully methylated oligonucleotide.

All values are the mean ± standard deviation of 3 replicate reactions.
OE33 gave an intermediate melt, suggesting that OE33 was partially methylated. Incubating the cells with vehicle for increasing lengths of time did not alter the normalised melt curves, nor the $T_{50}$, $T_{to}$, or $T_{td}$ (Table 4). Treatment with aza shifted the normalised melt curves to the left, with the degree of shift increasing with the length of treatment (Figure 4). The shifts in the normalised curves corresponded to a significant reduction in $T_{50}$, $T_{to}$ and $T_{td}$ when compared to vehicle. The $T_{do} - T_{to}$, a measure of methylation heterogeneity, decreased with length of aza treatment (Table 4). Methylation was confirmed by COBRA [13]. Similar shifts in the normalised melt curves were observed for MGMT (data not shown).

**Melt curve analysis of tissue DNA**

To demonstrate the utility of our melt analysis for detecting different patterns of methylation in tissue samples, methylation was measured in bisulfite modified DNA prepared from whole sections of FFPE CRC tissue with variable expression of MGMT as demonstrated by immunohistochemistry. Methylation of MGMT is associated with a reduction of its mRNA and protein expression in cancer cell lines and tissues [15,17]. Sections were taken from a single block of tissue that had either no, clonal, or complete loss of MGMT expression in the tumor cells. The normalised melt curves for a region of the MGMT promoter are shown in Figure 5. The CRC with no
detectable loss of MGMT expression by immunohistochemistry melted at the lowest temperature, that with clonal loss melted at an intermediate temperature. The $T_{50}$, $T_{to}$, $T_{td}$ and $T_{td} – T_{to}$ are presented in Table 5. The $T_{50}$ significantly increased with increasing loss of expression. There was no significant difference in the $T_{to}$ for unmethylated reference and any CRC tissue. The $T_{to}$ for the unmethylated reference and each of the CRC tissues were significantly less than the methylated reference, indicating the presence of unmethylated molecules in each of the CRC tissues. This would be expected due to the presence of stromal and other non-tumor cells in the tissue section. The $T_{td}$ for the methylated reference and each of the CRC tissues was significantly more than the unmethylated reference, indicating the presence of methylated molecules in all the CRC tissues, including the tissue with no detectable loss of MGMT protein expression. The patterns of methylation were confirmed by direct bisulfite sequencing (Additional File 1).

Discussion

We describe a simple method to quantitate DNA methylation using the raw fluorescence melt data obtainable following PCR amplification of bisulfite modified DNA. The method, which provides a summative measure of methylation at all the CpGs in the PCR product, is reproducible, sensitive, and informative whether the methylation in the region amplified is homogeneous or heterogeneous. While the differences due to methylation were apparent visually, key descriptive parameters ($T_{50}$, $T_{to}$, $T_{td}$ and $T_{td} – T_{to}$) could be calculated mathematically, which permits statistical analysis of results and eliminates the subjectivity of visual assessments. We validated the utility of the method with synthesised oligonucleotides and DNA prepared from fresh cells and formalin fixed paraffin embedded tissues.

In the PCR of bisulfite modified DNA, what were unmethylated cytosines in the genomic DNA will be amplified as thymines, and only methylated cytosines will be ampli-

**Table 4: $T_{50}$, $T_{to}$, $T_{td}$ and $T_{td} – T_{to}$ values for TIMP3 in OE33 cells treated with vehicle or 5-aza-2’-deoxycytidine**

| Sample | $T_{50}$ | $T_{to}$ | $T_{td}$ | $T_{td} – T_{to}$ |
|--------|---------|---------|---------|-----------------|
| U ref  | 75.52 ± 0.07 | 74.74 ± 0.16 | 77.36 ± 0.08 | 2.62 ± 0.24 |
| M ref  | 78.07 ± 0.23 | 77.26 ± 0.37 | 79.83 ± 0.02 | 2.57 ± 0.35 |
| veh 48 h | 76.87 ± 0.18 | 75.63 ± 0.29 | 79.37 ± 0.04 | 3.74 ± 0.29 |
| veh 72 h | 76.80 ± 0.11 | 75.56 ± 0.17 | 79.33 ± 0.07 | 3.77 ± 0.19 |
| veh 120 h | 76.89 ± 0.18 | 75.70 ± 0.33 | 79.34 ± 0.08 | 3.65 ± 0.36 |
| aza 48 h | 75.40 ± 0.66 | 73.84 ± 1.15 | 78.90 ± 0.09 | 5.05 ± 1.12 |
| aza 72 h | 75.54 ± 0.42 | 74.34 ± 0.75 | 78.69 ± 0.06 | 4.35 ± 0.74 |
| aza 120 h | 75.49 ± 0.33 | 74.38 ± 0.57 | 78.45 ± 0.19 | 4.07 ± 0.64 |

U ref – unmethylated reference.
M ref – methylated reference.
veh – OE33 esophageal adenocarcinoma cell line treated with vehicle for 48, 72 or 120 h.
aza – OE33 esophageal adenocarcinoma cell line treated with 1 μM 5-aza-2’-deoxycytidine for 48, 72 or 120 h.

Data shown for veh or aza treated OE33 are the mean ± standard deviation of triplicate reactions for each of triplicate cultures. Data shown for U ref and M ref are the mean ± standard deviation of triplicate reactions.
Several groups have used the melt curves from PCR products to detect mutations, polymorphisms or methylation. Worm [9], Akey [18] and Guldberg [19] detected methylated molecules to detect mutations, polymorphisms or methylation. Several groups have used the melt curves from PCR products to detect mutations, polymorphisms or methylation. Worm [9], Akey [18] and Guldberg [19] detected methylated molecules to detect mutations, polymorphisms or methylation.

Figure 4
Normalised melt curves of TIMP3 in OE33 cells treated with vehicle or 5-aza-2'-deoxycytidine. Triplicate cultures of esophageal adenocarcinoma cell line OE33 were treated with either vehicle (veh) or 1 μM 5-aza-2'-deoxycytidine (aza) for 48, 72, or 120 h. Bisulfite modified DNA from treated OE33, unmethylated reference (U ref) and methylated reference (M ref) was amplified using the TIMP3 primers, melted, and the fluorescence normalised. Data shown for veh or aza treated OE33 are the mean ± standard deviation of triplicate reactions for each of triplicate cultures. Data shown for U ref and M ref are the mean ± standard deviation of triplicate reactions.

Our method is based on normalising the raw melt fluorescence data using a simple algorithm which is easily computerised. It is easy to assess methylation visually from the normalised melt curve, but the power of the method is that it permits a mathematical analysis of the methylation. From the normalised melt data we calculate four parameters which describe the methylation status of the amplified region. The Tto, the temperature at which melting begins, reflects the least methylated amplicons present. The Ttd, the temperature at which the product is completely melted, reflects the most methylated amplicons present. The Ttd – Tto reflects the heterogeneity of the amplicons with respect to methylation. If Ttd – Tto is small, most alleles have a similar amount of methylation, if it is large then some alleles are high in methylation, others low. The T50 is the temperature at which half of the amplicons are melted, and reflects the sum of all methylation of all the CpGs in the amplified region. The more the methylation in a region, the higher the T50. Because these parameters are derived mathematically, the subjectivity of other melt curve analytical methods is eliminated.

To validate our method we first used synthesised oligonucleotides representing a bisulfite modified sequence from
the CDKN2A promoter in its methylated, unmethylated and partially methylated form to show that the shape of the normalised melt curve, and the temperature at which the melting commenced and was completed, reflected the degree of methylation of the template alleles. We then demonstrated the utility of the method in more the complex situation of analysing DNA preparations from fresh cells and formalin fixed paraffin embedded tissues. Using lymphocyte DNA methylated with CpG methylase diluted into unmethylated lymphocyte DNA we showed a linear relationship between T50 and the percentage of methylated amplicons in the mixture. The method could unambiguously detect methylation in samples containing between 1–5% of methylated DNA, depending on the target sequence. We were able to quantitate the anticipated reduction in methylation (T50) and methylation heterogeneity (Ttd – Tto) over time in a cell line treated with the demethylating agent 5-aza-2’-deoxycytidine. Finally, we could quantitate differences in methylation associated with complete, clonal or no loss of expression of MGMT expression in formalin fixed paraffin embedded tissues. Our melt analysis of methylation was confirmed by bisulfite sequencing.

The melt curve analysis is a valuable addition to the methods available for measuring methylation. The most common method for the analysis of methylation is methylation specific PCR (MSP), which uses primers that are specific for either methylated, or unmethylated, bisulfite modified DNA. This technique relies on 3’ mismatching of the PCR primers for specificity. False positives can occur if the primers are poorly designed or the PCR is run at too low a temperature, or possibly for too many cycles. The method is sensitive, but only measures methylation of one or two CpGs located near the 3’ end of the primers and is not quantitative. Tumors can be classified as methylated when only a minor percentage of cells are methylated, or if the bisulfite conversion of the DNA is incomplete (with some unmethylated cytosines remaining as cytosines, not being converted to uracils).

Pyrosequencing accurately quantifies DNA methylation levels for multiple CpG sites within the PCR product, but it requires more expensive, biotin labeled primers, and a pyrosequencer in addition to a PCR thermocycler. MethyLight is an extremely sensitive and quantitative assay which uses TaqMan technology to measure methylation, utilising the cleavage of a dual-labeled fluorogenic hybridization probe by the 5’ nuclease activity of Taq polymerase during the PCR amplification. The probes are expensive, and are specific for a particular methylation pattern within the amplified region. Generally the probes are designed to detect the fully methylated or fully unmethylated allele only, not partially methylated alleles. Bisulfite sequencing is the gold standard for methylation analysis, but is time consuming and expensive, and its accuracy is limited by the number of clones which are sequenced. Melt curve analysis is rapid and cost-effective method to quantitate DNA methylation when information about the summative methylation of the amplified region is required. Unlike MSP, it is quantitative and does not generate false positives. Unlike pyrosequencing it does not require equipment other than a PCR thermocycler, and unlike MethyLight it resolves heterogeneous methylation and can quantitate mixtures of variably methylated molecules in the same reaction, and does not require specific probes. It is much quicker than bisulfite sequencing, but does not provide the same detail about the pattern of methylation. It is particularly suited to measuring methylation in CpG rich regions, such as CpG islands associated with the promoter regions of genes, where it is generally sufficient to measure average CpG methylation levels rather than the level for every single CpG [20]. If high resolution methylation detail is required, such as can be provided by bisulfite sequencing, melt curve analysis can be used to screen for samples or clones which are unmethylated and do not require further analysis.

Two modifications have the potential to improve the performance of the method, although the principles of the analysis would not change. Fluorescent dyes such as SYTO9, LC Green or Eva Green which do not redistribute during melting may improve the detection of minor unmethylated populations, increasing sensitivity. Instruments which acquire fluorescence data with greater accuracy and over smaller temperature increments (e.g., 0.01 °C compared to 0.5 °C with the RG3000 used in this study) would also be expected to improve the sensitivity of the assay.

Conclusion
We have developed a rapid, reproducible and cost-effective in-tube assay to quantitate DNA methylation which yields significant information about the methylation in the template DNA. It resolves heterogeneous methylation, quantitating the total methylation when there are mix-

| Sample    | T50 ± SD | Tto ± SD | Ttd ± SD | Ttd – Tto ± SD |
|-----------|----------|----------|----------|----------------|
| U ref     | 76.17 ± 0.07 | 73.70 ± 0.09 | 80.32 ± 0.45 | 6.62 ± 0.40 |
| M ref     | 75.84 ± 0.21 | 73.62 ± 0.17 | 81.12 ± 0.37 | 7.50 ± 0.31 |
| No        | 74.18 ± 0.09 | 73.54 ± 0.06 | 77.24 ± 1.01 | 3.71 ± 0.95 |
| Clonal    | 74.17 ± 0.04 | 73.64 ± 0.04 | 75.54 ± 0.04 | 1.90 ± 0.03 |
| Complete  | 78.70 ± 0.19 | 78.06 ± 0.37 | 80.43 ± 0.15 | 2.36 ± 0.25 |
| M ref     | 75.84 ± 0.21 | 73.62 ± 0.17 | 81.12 ± 0.37 | 7.50 ± 0.31 |
| U ref     | 78.70 ± 0.19 | 78.06 ± 0.37 | 80.43 ± 0.15 | 2.36 ± 0.25 |
| Complete  | 76.17 ± 0.07 | 73.70 ± 0.09 | 80.32 ± 0.45 | 6.62 ± 0.40 |
Normalised melt curves of MGMT in formalin fixed paraffin embedded colorectal carcinoma tissues.

DNA was isolated from whole sections of FFPE CRC tissues that had either no, clonal, or complete loss of MGMT expression as demonstrated by immunohistochemistry. Bisulfite modified DNA from CRC tissues, unmethylated reference (U ref) and methylated reference (M ref) was amplified using MGMT primers, melted and the fluorescence normalised. Data shown are the mean ± standard deviation of six replicate reactions.

Figure 5

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

ES undertook the laboratory component of the study and participated in the design of the study, the analysis of the results, and the drafting the manuscript. MEJ participated in the design of the study and wrote the software for the melt analysis. PAD participated in the design of the study, the analysis of the results and the drafting of the manuscript. Each author read and approved the final manuscript.

Acknowledgements

This study was supported by The Cancer Council of South Australia Research Grant 453588, the National Health and Medical Research Council Project Grant 275504. We wish to thank Dr Andrew Ruszkiewicz for contributing the FFPE CRC tissue and MGMT immunohistochemistry used in this study. We wish to thank Catherine Howard for her assistance in the preparation of the manuscript.

References

1. Fraga MF, Esteller M: DNA methylation: a profile of methods and applications. Biotechniques 2002, 33:632, 634, 636–649.
2. Wong IH: Qualitative and quantitative polymerase chain reaction-based methods for DNA methylation analyses. Methods Mol Biol 2006, 336:33-43.
3. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL: A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 1992, 89:1827-1831.
4. Tost J, Dunker J, Gut IG: Analysis and quantification of multiple methylation variable positions in CpG islands by Pyrosequencing. Biotechniques 2003, 35:152-156.
5. Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarios G, Cantor CR, Field JK, Boom D van den: Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci USA 2005, 102:15785-15790.
6. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93:8892-8896.
7. Ririe KM, Rasmussen RP, Wittwer CT: Product differentiation by analysis of DNA melting curves during the polymerase chain reaction. Anal Biochem 1997, 245:154-160.
8. Wittwer CT, Reed GH, Gundry CN, Vandersteen JG, Pryor RJ: High-resolution genotyping by amplicon melting analysis using LCGreen. Clin Chem 2003, 49:853-860.
9. Worm J, Aggerholm A, Guldberg P: In-tube DNA methylation profiling by fluorescence melting curve analysis. Clin Chem 2001, 47:1183-1189.
10. Wojdacz TK, Dobrovic A: Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res 2007, 35:e41.
11. Fragola J, Song J, Stizraker C, Hinselwood RA, Peinado MA, Clark SJ: Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet 2006, 38:540-549.
12. Lorente A, Mueller W, Urdangarin E, Lazzoz P, von Deimling A, Castresana JS: Detection of methylation in promoter sequences.
by melting curve analysis-based semiquantitative real time PCR. BMC Cancer 2008, 8:61.

13. Smith E, Drew PA, Tian ZQ, De Young NJ, Liu JF, Mayne GC, Ruszkiewicz AR, Watson DJ, Jamieson GG: Metallothionein 3 expression is frequently down-regulated in oesophageal squamous cell carcinoma by DNA methylation. Mol Cancer 2005, 4:42.

14. Smith E, De Young NJ, Tian ZQ, Caruso M, Ruszkiewicz AR, Liu JF, Jamieson GG, Drew PA: Methylation of TIMP3 in esophageal squamous cell carcinoma. World J Gastroenterol 2008, 14:203-210.

15. Smith E, De Young NJ, Pavey SJ, Hayward NK, Nancarrow DJ, Whiteman DC, Smithers BM, Ruszkiewicz AR, Clouston AD, Godley DC, et al.: Similarity of aberrant DNA methylation in Barrett’s oesophagus and oesophageal adenocarcinoma. Mol Cancer 2008, 7:75.

16. Siegel S, Castellan NJ: Nonparametric statistics for the behavioral sciences Second edition. Singapore: McGraw-Hill Inc.; 1988.

17. Nagasaka T, Goel A, Notohara K, Takahata T, Sasamoto H, Uchida T, Nishida N, Tanaka N, Boland CR, Matsubara N: Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis. Int J Cancer 2008, 122:2429-2436.

18. Akey DT, Akey JM, Zhang K, Jin L: Assaying DNA methylation based on high-throughput melting curve approaches. Genomics 2002, 80:376-384.

19. Guldberg P, Worm J, Gronbaek K: Profiling DNA methylation by melting analysis. Methods 2002, 27:121-127.

20. Bock C, Walter J, Paulsen M, Lengauer T: Inter-individual variation of DNA methylation and its implications for large-scale epigenome mapping. Nucleic Acids Res 2008, 36:e55.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2407/9/123/prepub